Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 5,196 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thoracic Cancer Clear all
Completed Phase 2 Interventional Results available

Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC

NCT00517595
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pemetrexed and Gemcitabine plus Bevacizumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
Waterbury, Connecticut • Augusta, Georgia • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Oct 20, 2026, 1:47 PM EDT
Suspended No phase listed Observational

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2

NCT03253575
View directory record Official record
Conditions
Adult Solid Tumor
Interventions
CANscript
Diagnostic Test
Lead sponsor
Mitra RxDx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Timeline
2017 – 2019
U.S. locations
30
States / cities
Gilbert, Arizona • Aurora, Colorado • Norwich, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 20, 2026, 1:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT00046839
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
44
States / cities
Colorado Springs, Colorado • Gainesville, Florida • Jacksonville, Florida + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 20, 2026, 1:47 PM EDT
Terminated No phase listed Observational Results available

Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer

NCT02762877
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
Not listed
Lead sponsor
Genomic Health®, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Torrance, California • Macon, Georgia • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 20, 2026, 1:47 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257
View directory record Official record
Conditions
Limited-Stage Small Cell Lung Cancer
Interventions
HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)
Drug · Radiation
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
31
States / cities
Arcadia, California • Los Alamitos, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 20, 2026, 1:47 PM EDT
Completed Phase 1 Interventional

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

NCT02088112
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Gefitinib, MEDI4736
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 130 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Tampa, Florida • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 20, 2026, 1:47 PM EDT
Completed Phase 2 Interventional

Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00114192
View directory record Official record
Conditions
Lung Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Oct 20, 2026, 1:47 PM EDT
Not listed Early Phase 1 Interventional

Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management

NCT06060964
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage I, Lung Cancer Stage II, Lung Cancer Stage III
Interventions
Breathe Easier Progressive Web Application
Other
Lead sponsor
University of South Carolina
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 20, 2026, 1:47 PM EDT
Terminated Not applicable Interventional

Exercise as Maintenance Therapy in Advanced Lung Cancer

NCT06513663
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Metastatic Lung Cancer
Interventions
Exercise Intervention
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 20, 2026, 1:47 PM EDT
Terminated Phase 1 Interventional

Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

NCT00629187
View directory record Official record
Conditions
Central Nervous System Neoplasms, Neoplasm Metastasis
Interventions
Temozolomide
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 20, 2026, 1:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

NCT06162221
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
Interventions
RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, RMC-9805
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
Gilbert, Arizona • Duarte, California • Irvine, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 1:47 PM EDT
Completed Phase 2 Interventional

CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer

NCT00033384
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Interventions
CI-1040
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 20, 2026, 1:47 PM EDT
Active, not recruiting Phase 2 Interventional

Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer

NCT06660407
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Immunotherapy, Palliative Radiation Therapy, Spatially-fractionated Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 1:47 PM EDT
Completed Phase 3 Interventional

Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis

NCT05369234
View directory record Official record
Conditions
Oral Cavity Cancer, Head and Neck Cancers - Tonsils, Esophageal Cancer, Laryngeal Cancer, Oropharynx Cancer, Mediastinal Cancer, Chest Wall Tumor, Radiation Mucositis
Interventions
100% Aloe Vera Juice, Magic Mouthwash, Salt and Baking soda rinse, Carafate
Dietary Supplement · Combination Product · Drug
Lead sponsor
Covenant Health Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 20, 2026, 1:47 PM EDT
Suspended Phase 1 Interventional

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

NCT03392064
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
AMG 119
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 20, 2026, 1:47 PM EDT
Completed Phase 2 Interventional Results available

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

NCT00548093
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung
Interventions
PF-00299804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
19
States / cities
Duarte, California • Pasadena, California • South Pasadena, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 20, 2026, 1:47 PM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 20, 2026, 1:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

NCT05558904
View directory record Official record
Conditions
Lung Adenocarcinoma
Interventions
Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside, Computed Tomography, Laboratory Biomarker Analysis, Positron Emission Tomography
Drug · Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 20, 2026, 1:47 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00005838
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
shark cartilage extract AE-941, placebo, cisplatin, vinorelbine tartrate, carboplatin, paclitaxel, radiation therapy
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 20, 2026, 1:47 PM EDT
Active, not recruiting Phase 2 Interventional

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448
View directory record Official record
Conditions
Lung Cancer
Interventions
Osimertinib, Cisplatin or Carboplatin; Pemetrexed or Paclitaxel, Radiation
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
La Jolla, California • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 1:47 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Pilot Study of Model Based Iterative Reconstruction Using 64-Slice

NCT01431378
View directory record Official record
Conditions
Posterior Fossa Hemorrhage, Lung Cancer, Flank Pain, Urolithiasis, Focal Hepatic Necrosis
Interventions
Not listed
Lead sponsor
GE Healthcare
Industry
Eligibility
30 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • Miwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 20, 2026, 1:47 PM EDT
Terminated Phase 2 Interventional Results available

S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00265785
View directory record Official record
Conditions
Lung Cancer
Interventions
pemetrexed
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
112
States / cities
Anchorage, Alaska • Jonesboro, Arkansas • Los Angeles, California + 67 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 20, 2026, 1:47 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer

NCT00728845
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, hydroxychloroquine, paclitaxel
Biological · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 20, 2026, 1:47 PM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 20, 2026, 1:47 PM EDT